Octreotide and Graves' ophthalmopathy and pretibial myxoedema.
作者信息
Chang T C, Kao S C, Huang K M
机构信息
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Republic of China.
出版信息
BMJ. 1992 Jan 18;304(6820):158. doi: 10.1136/bmj.304.6820.158.
Abstract
摘要
相似文献
1
Octreotide and Graves' ophthalmopathy and pretibial myxoedema.奥曲肽与格雷夫斯眼病和胫前黏液性水肿
BMJ. 1992 Jan 18;304(6820):158. doi: 10.1136/bmj.304.6820.158.
2
Oral pentoxifylline and topical clobetasol propionate ointment in the treatment of pretibial myxoedema, with concomitant improvement of Graves' ophthalmopathy.口服己酮可可碱和外用丙酸氯倍他索软膏治疗胫前黏液性水肿，并同时改善格雷夫斯眼病。
J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1441-3. doi: 10.1111/j.1468-3083.2007.02259.x.
3
Graves' dermopathy: does octreotide scintigraphy predict the response to octreotide treatment?
Thyroid. 1996 Oct;6(5):385-9. doi: 10.1089/thy.1996.6.385.
4
Refractory pretibial myxoedema with response to intralesional insulin-like growth factor 1 antagonist (octreotide): downregulation of hyaluronic acid production by the lesional fibroblasts.
Br J Dermatol. 2000 Nov;143(5):1083-6. doi: 10.1046/j.1365-2133.2000.03850.x.
5
Graves' disease with pretibial myxedema.格雷夫斯病伴胫前黏液性水肿。
Arch Dermatol. 1969 Jan;99(1):117-9. doi: 10.1001/archderm.99.1.117.
6
Orbital decompression in Graves' ophthalmopathy associated with pretibial myxedema.格雷夫斯眼病合并胫前黏液性水肿的眼眶减压术
J Endocrinol Invest. 1993 Jun;16(6):433-7. doi: 10.1007/BF03348875.
7
Triad of exophthalmos, pretibial myxedema, and acropachy in a patient with Graves' disease.一名格雷夫斯病患者出现突眼、胫前黏液性水肿和杵状指三联征。
J Am Acad Dermatol. 2003 Jun;48(6):970-2. doi: 10.1067/mjd.2003.323.
8
Pretibial myxedema as the initial manifestation of Graves' disease.胫前黏液性水肿作为格雷夫斯病的初始表现。
J Eur Acad Dermatol Venereol. 2002 Jul;16(4):380-3. doi: 10.1046/j.1468-3083.2002.00567.x.
9
[An integrated approach to the treatment of pretibial myxedema based on pulse therapy with prednisolone and electrical neuromyostimulation (FREMS-therapy) in a patient with Graves' disease and thyroid eye disease].[基于泼尼松龙脉冲疗法和电神经肌肉刺激（FREMS疗法）对一名患有格雷夫斯病和甲状腺眼病患者的胫前黏液性水肿进行综合治疗]
Probl Endokrinol (Mosk). 2023 Aug 30;69(4):32-37. doi: 10.14341/probl12888.
10
Pretibial myxedema and high-dose intravenous immunoglobulin treatment.胫前黏液性水肿与大剂量静脉注射免疫球蛋白治疗
Thyroid. 1994 Winter;4(4):399-408. doi: 10.1089/thy.1994.4.399.
引用本文的文献
1
Octreotide inhibits secretion of IGF-1 from orbital fibroblasts in patients with thyroid-associated ophthalmopathy via inhibition of the NF-κB pathway.奥曲肽通过抑制 NF-κB 通路抑制甲状腺相关眼病患者眼眶成纤维细胞 IGF-1 的分泌。
PLoS One. 2021 Apr 22;16(4):e0249988. doi: 10.1371/journal.pone.0249988. eCollection 2021.
2
Somatostatin Analogs in Clinical Practice: a Review.生长抑素类似物在临床实践中的应用：综述。
Int J Mol Sci. 2020 Feb 29;21(5):1682. doi: 10.3390/ijms21051682.
3
Locally produced insulin-like growth factor-1 by orbital fibroblasts as implicative pathogenic factor rather than systemically circulated IGF-1 for patients with thyroid-associated ophthalmopathy.眼眶成纤维细胞局部产生的胰岛素样生长因子-1 是甲状腺相关眼病的致病因素，而非循环系统中的 IGF-1。
Graefes Arch Clin Exp Ophthalmol. 2012 Mar;250(3):433-40. doi: 10.1007/s00417-011-1876-5. Epub 2011 Dec 9.
4
The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease.生长抑素类似物在治疗糖尿病视网膜病变和甲状腺眼病中的疗效。
Clin Ophthalmol. 2007 Sep;1(3):209-15.
5
Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.长效兰瑞肽治疗格雷夫斯眼病：一项双盲随机、安慰剂对照临床试验。
J Endocrinol Invest. 2006 May;29(5):413-22. doi: 10.1007/BF03344124.
6
The cost of immunosuppressive therapies currently used in patients with thyroid eye disease.目前用于甲状腺眼病患者的免疫抑制疗法的成本。
J Endocrinol Invest. 2004 Nov;27(10):919-23. doi: 10.1007/BF03347533.
7
Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.兰瑞肽治疗一名干扰素相关性格雷夫斯眼病患者。
Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):269-72. doi: 10.1007/s00417-004-1012-x. Epub 2004 Sep 28.
8
Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy.生长抑素类似物：一种用于治疗Graves眼病的新工具。
J Endocrinol Invest. 2004 Mar;27(3):281-7. doi: 10.1007/BF03345278.
9
Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.格雷夫斯眼病免疫抑制和放疗管理的新进展。
J Endocrinol Invest. 2004 Mar;27(3):272-80. doi: 10.1007/BF03345277.
10
Somatostatin-receptor scintigraphy in Graves' orbitopathy.
Eur J Nucl Med. 1996 Jun;23(6):615-7. doi: 10.1007/BF00834521.
本文引用的文献
1
SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.SMS 201 - 995：一种非常强效且具选择性的生长抑素八肽类似物，作用持久。
Life Sci. 1982 Sep 13;31(11):1133-40. doi: 10.1016/0024-3205(82)90087-x.
2
Pathogenesis and treatment of pretibial myxedema.胫前黏液性水肿的发病机制与治疗
Endocrinol Metab Clin North Am. 1987 Jun;16(2):409-15.
3
Somatomedin C in pathogenesis of malignant exophthalmos of endocrine origin.生长调节素C在内分泌源性恶性突眼症发病机制中的作用
Lancet. 1986 Jan 25;1(8474):218-9. doi: 10.1016/s0140-6736(86)90698-7.
4
Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells.生长抑素抑制促甲状腺激素和胰岛素样生长因子-I在FRTL5细胞中诱导的脱氧核糖核酸合成。
Endocrinology. 1990 Jun;126(6):3131-8. doi: 10.1210/endo-126-6-3131.
Zotero 插件